Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07321678
PHASE2

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Sponsor: Ascletis Pharma (China) Co., Limited

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus

Official title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2026-01

Completion Date

2026-08

Last Updated

2026-01-07

Healthy Volunteers

No

Interventions

DRUG

ASC30 tablets

ASC30 tablets administered orally once daily

DRUG

Placebo

Placebo administered orally once daily

Locations (8)

Ascletis Clinical Site

Riverside, California, United States

Ascletis Clinical Site

San Jose, California, United States

Ascletis Clinical Site

Denver, Colorado, United States

Ascletis Clinical Site

Miami, Florida, United States

Ascletis Clinical Site

Miami, Florida, United States

Ascletis Clinical Site

Decatur, Georgia, United States

Ascletis Clinical Site

Springfield, Missouri, United States

Ascletis Clinical Site

San Antonio, Texas, United States